ClinicalTrials.gg
CompletedNCT05149313ADvantageUpdated May 20, 2025Results posted

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine

A Phase 3 interventional study of Lebrikizumab and Lebrikizumab-matching Placebo in Dermatitis, Atopic and Eczema, sponsored by Almirall, S.A.. Completed at 48 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
7th of 24
331 · median 252
Started
2021
with 1 other
Phase 3
17 of 24
2 open now
Registered
11th of 24
by date
Lead sponsor
5 of 24
Almirall, S.A.

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.

03

Conditions studied

  • Dermatitis, Atopic
  • Eczema

Keywords

  • Topical Corticosteroids
  • Cyclosporine
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and adolescents (aged greater than or equal to (>=) 12 to \<18 years at the time of Form (ICF)/Informed Assent Form (IAF) and weighing >=40 kilograms).
  • Chronic AD that has been present for >=1 year before the Screening visit.
  • EASI score >=16 at the Baseline Visit.
  • IGA score >=3 (moderate) (scale of 0 [clear] to 4 [severe]) at the Baseline visit.
  • >=10% BSA of AD involvement at the Baseline visit.
  • Inadequate response to existing topical medications
  • Failure to cyclosporine or non-medically advisable to receive/continue receiving cyclosporine
  • Signed ICF (and informed assent for adolescents as required)

Exclusion criteria

Exclusion Criteria:

  • Treatment with TCS within 1 week before the Baseline visit.
  • Treatment with topical calcineurin inhibitors, phosphodiesterase-4 inhibitors such as crisaborole, or cannabinoids within 2 week before the Baseline visit.
  • Treatment with interleukin 4 (IL-4) or interleukin 13 (IL-13) antagonists biological therapies before the Baseline visit. Exception: previous treatment with dupilumab will be allowed in a subset of patients
  • Treatment with /immunomodulating drugs, phototherapy and photochemotherapy within 4 weeks before the Baseline visit
  • Uncontrolled chronic disease that might require bursts of oral
  • Serious, opportunistic, chronic or recurring infections within 3 months of Screening or before randomization
  • Current or chronic infection with virus, current infection with virus, known liver cirrhosis and/or chronic hepatitis of any etiology
  • Known or suspected history of immunosuppression, history of infection or positive HIV serology at Screening
  • Any laboratory test results obtained at the Screening visit
  • Presence of skin comorbidities that may interfere with study assessments
  • Have had an important side effect to TCS that would prevent further use.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Lebrikizumab administered subcutaneously (SC), participants will receive 2 injections of lebrikizumab 250 mg at Baseline and Week 2, followed by 1 injection of lebrikizumab 250 milligram (mg) once every two weeks (Q2W) in the induction period up to week 16. Participants who received lebrikizumab 250 mg Q2W during the Induction Period will continue to receive lebrikizumab 250 mg Q2W during the Maintenance Period. In order to maintain the double blind, participants from the lebrikizumab 250 mg Q2W arm will be administered a second injection of blinded placebo during Week 16 and Week 18. From Week 20 up to Week 52, all participants will receive 1 injection of lebrikizumab 250 mg Q2W in Open-label maintenance period.

    Biological: Lebrikizumab

  • Placebo comparator
    Lebrikizumab-matching Placebo

    Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections of lebrikizumab 250 mg at Week 16 and Week 18 followed by 1 injection of lebrikizumab 250 mg Q2W from Week 20 up to Week 52 in Open-label maintenance period.

    Drug: Lebrikizumab-matching Placebo

Interventions

  • BiologicalLebrikizumab

    Lebrikizumab solution for injection administered subcutaneously.

  • DrugLebrikizumab-matching Placebo

    Matching Placebo solution for injection administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16

    The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

    Time frame: At Week 16

Secondary outcomes

  1. Double-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 16

    The IGA is an instrument used to globally rate the severity of the participants AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).

    Time frame: At Week 16

  2. Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 16

    The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable. Higher score indicates more severity.

    Time frame: At Week 16

  3. Double-blind Induction Period: Percentage of Participants Who Achieved EASI 75 (>=75% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, and 12

    The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease. Percentage of participants who achieved EASI 75 (\>=75% reduction from baseline in EASI score) at Weeks 2, 4, 8, and 12 were reported

    Time frame: At Weeks 2, 4, 8, and12

  4. Double-blind Induction Period: Percentage of Participants Who Achieved EASI 90 (>=90% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16

    The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  5. Double-blind Induction Period: Percentage of Participants Who Achieved EASI 50 (>=50% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16

    The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  6. Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Dermatology Life Quality Index (DLQI) at Weeks 2, 4, 8, 12 and 16

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  7. Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Children's Dermatology Life Quality Index (CDLQI) at Weeks 2, 4, 8, 12 and 16

    The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  8. Double-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 16

    The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") and 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain.

    Time frame: At Week 16

  9. Double-blind Induction Period: Change From Baseline in Body Surface Area (BSA) at Weeks 2, 4, 8, 12 and 16

    The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of total body surface. BSA was determined by the Investigator or designee using the participant palm = 1% BSA rule. The participant's palm is measured from the wrist to the proximal interphalangeal and thumb. This higher the BSA %, the more active atopic dermatitis is present. Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD and negative change from baseline indicate no severity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 16

  10. Double-blind Induction Period: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 8 and 16

    SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: A) Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s and reported as the sum of all areas, with a score ranging from 0-100. B) Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item graded as: none (0), mild (1), moderate (2), or severe (3). C) Subjective assessment of itch and of sleeplessness is recorded for each symptom using a visual analogue scale (VAS), where 0=no itch (or no sleeplessness) and 10= worst imaginable itch (or sleeplessness), with maximum score of 20. Formula is: A/5+7B/2+C, A: extent (0-100), B: intensity (0-18), C: subjective symptoms (0-20). SCORAD total score ranged from 0 (no disease) to 103 (severe disease). Higher values represent worse outcome and negative change from baseline indicate improvement.

    Time frame: Baseline, Weeks 8 and 16

  11. Double-blind Induction Period: Change From Baseline in Pruritus NRS by Week up to Week 16

    The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable." Higher scores indicated greater severity and negative change from baseline indicate no severity.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16

  12. Double-blind Induction Period: Change From Baseline in the Sleep Loss at Week 16 Using Patient-related Outcome (PRO) by Week up to Week 16

    Sleep loss was assessed by all participants using a PRO instrument. Participants (and if applicable, with help of parents/caregiver if required) rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Higher scores indicated a greater impact and worse outcome; therefore, negative change from baseline indicate less impact.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16

  13. Double-blind Induction Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Weeks 4, 8, 12 and 16

    The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1 to 2 days = 1; 3 to 4 days = 2; 5 to 6 days = 3; every day = 4. Higher scores indicated more severe disease and poor quality of life (QoL); therefore, negative change from baseline indicate improvement in QoL.

    Time frame: Baseline, Weeks 4, 8, 12 and 16

  14. Double-blind Induction Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 2. 4, 8, 12 and 16

    The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL and negative change from baseline indicate improvement in QoL.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 16

  15. Double-blind Induction Period: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2. 4, 8, 12 and 16

    The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL and negative change from baseline indicate low impact on QoL.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 16

  16. Double-blind Induction Period: Change From Baseline in Skin Pain NRS by Week up to Week 16

    The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") to 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain and negative change from baseline indicate no pain.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16

  17. Double-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days

    TCS free days proportion = Number of days participant did not take TCS medication / Number of days from Baseline to Week 16 Date or early discontinuation

    Time frame: Baseline up to Week 16

  18. Double-blind Induction Period: Median Time (Days) to TCS-Free Use

    Days from first study drug injection to the day participant stopped using all TCS.

    Time frame: Baseline up to Week 16

07

Results

Posted Nov 6, 2024

Participant flow

Study was conducted at 54 sites in Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Spain, and United Kingdom. Randomization was stratified by previous use of dupilumab, age (adolescent participants aged \>=12 to \< 18 years comprises 11.8% of the overall population compared to adults aged \>=18 years) and baseline disease severity (IGA 3 vs 4).

Double-blind Induction Period (16-weeks)
Participant flow — Double-blind Induction Period (16-weeks)
MilestoneDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSOpen-label Maintenance Period: Lebrikizumab to LebrikizumabOpen-label Maintenance Period: Placebo to Lebrikizumab
Started22011100
Completed21210000
Not completed81100
Withdrew: Adverse event2200
Withdrew: Lost to follow-up2300
Withdrew: Pregnancy1000
Withdrew: Withdrawal by subject2500
Withdrew: Physician decision1000
Withdrew: Other0100
Open-label Maintenance Period (36 Weeks)
Participant flow — Open-label Maintenance Period (36 Weeks)
MilestoneDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSOpen-label Maintenance Period: Lebrikizumab to LebrikizumabOpen-label Maintenance Period: Placebo to Lebrikizumab
Started00212100
Completed0018087
Not completed003213
Withdrew: Adverse event0071
Withdrew: Withdrawal by subject00147
Withdrew: Lack of efficacy0065
Withdrew: Lost to follow-up0040
Withdrew: Protocol deviation0010

Outcome measures

PrimaryDouble-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16

The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 1668.440.8
Statistical analysis
  • Double-blind Induction Period: Lebrikizumab +TCS vs Double-blind Induction Period: Placebo +TCS · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentages: 27.88 · 95% CI 15.63 to 40.14
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 16

The IGA is an instrument used to globally rate the severity of the participants AD. It is based on a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe), and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting (minimal, palpable induration and significant induration). Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Percentage of Participants Who Achieved Investigator Global Assessment (IGA) Score of 0 or 1 and 2-point Improvement at Week 1642.024.5
Statistical analysis
  • Double-blind Induction Period: Lebrikizumab +TCS vs Double-blind Induction Period: Placebo +TCS · Cochran-Mantel-Haenszel · p = 0.0052 · Difference in percentages: 17.80 · 95% CI 7.03 to 28.57
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 16

The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable. Higher score indicates more severity.

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Pruritus Numeric Rating Score (NRS) at Week 1649.929.7
Statistical analysis
  • Double-blind Induction Period: Lebrikizumab +TCS vs Double-blind Induction Period: Placebo +TCS · Cochran-Mantel-Haenszel · p = 0.0114 · Difference in percentages: 18.15 · 95% CI 5.47 to 30.83
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved EASI 75 (>=75% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, and 12

The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease. Percentage of participants who achieved EASI 75 (\>=75% reduction from baseline in EASI score) at Weeks 2, 4, 8, and 12 were reported

Time frame:
At Weeks 2, 4, 8, and12
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 75 (>=75% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, and 12
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
At Week 29.76.3
At Week 428.319.2
At Week 854.931.5
At Week 1264.941.1
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved EASI 90 (>=90% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16

The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 90 (>=90% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
At Week 21.50.9
At Week 415.86.4
At Week 828.910.6
At Week 1242.121.0
At Week 1642.920.8
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved EASI 50 (>=50% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16

The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. The severity of the clinical signs of AD for each of 4 body regions was scored on a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe. The area of AD involvement on each of the 4 anatomic regions was assessed as a percentage by body area: 0=no eruption, 1=1% to 9%, 2=10% to 29%, 3=30% to 49%, 4=50% to 60%, 5=70% to 80% and 6=90% to 100%. The composite index with total score ranged from 0 to 72, where higher scores indicates more severe and or extensive disease.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved EASI 50 (>=50% Reduction From Baseline in EASI Score) at Weeks 2, 4, 8, 12 and 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
At Week 230.823.4
At Week 458.946.0
At Week 875.259.3
At Week 1280.368.0
At Week 1682.665.3
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Dermatology Life Quality Index (DLQI) at Weeks 2, 4, 8, 12 and 16

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Dermatology Life Quality Index (DLQI) at Weeks 2, 4, 8, 12 and 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
At Week 252.857.1
At Week 466.161.9
At Week 870.556.1
At Week 1273.159.6
At Week 1678.069.6
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Children's Dermatology Life Quality Index (CDLQI) at Weeks 2, 4, 8, 12 and 16

The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved a 4-point Improvement in Children's Dermatology Life Quality Index (CDLQI) at Weeks 2, 4, 8, 12 and 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
At Week 290.9100
At Week 468.262.5
At Week 890.9100
At Week 1295.5100
At Week 1693.1100
SecondaryDouble-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 16

The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") and 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain.

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Double-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 16
Percentage of participantsDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Percentage of Participants Who Achieved a 4- Point Improvement in Skin Pain NRS at Week 1651.627.5
SecondaryDouble-blind Induction Period: Change From Baseline in Body Surface Area (BSA) at Weeks 2, 4, 8, 12 and 16

The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of total body surface. BSA was determined by the Investigator or designee using the participant palm = 1% BSA rule. The participant's palm is measured from the wrist to the proximal interphalangeal and thumb. This higher the BSA %, the more active atopic dermatitis is present. Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD and negative change from baseline indicate no severity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Percentage of body surface area
Double-blind Induction Period: Change From Baseline in Body Surface Area (BSA) at Weeks 2, 4, 8, 12 and 16
Percentage of body surface areaDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-11.4 ± 15.33-10.6 ± 12.04
Change at Week 4-19.5 ± 19.22-15.3 ± 13.77
Change at Week 8-27.3 ± 20.60-19.2 ± 17.12
Change at Week 12-30.6 ± 21.25-22.5 ± 17.06
Change at Week 16-32.5 ± 21.44-22.1 ± 18.57
SecondaryDouble-blind Induction Period: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 8 and 16

SCORAD is a validated clinical tool for assessing the extent and intensity of AD. There are 3 components: A) Surface involvement is assessed as proportion of involved surface area segment by segment by applying the rule of 9s and reported as the sum of all areas, with a score ranging from 0-100. B) Intensity part of the SCORAD consists of 6 items: erythema, oedema, oozing/crusting, excoriation, lichenification, and dryness. Each item graded as: none (0), mild (1), moderate (2), or severe (3). C) Subjective assessment of itch and of sleeplessness is recorded for each symptom using a visual analogue scale (VAS), where 0=no itch (or no sleeplessness) and 10= worst imaginable itch (or sleeplessness), with maximum score of 20. Formula is: A/5+7B/2+C, A: extent (0-100), B: intensity (0-18), C: subjective symptoms (0-20). SCORAD total score ranged from 0 (no disease) to 103 (severe disease). Higher values represent worse outcome and negative change from baseline indicate improvement.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 8 and 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 8-32.1 ± 17.90-20.0 ± 18.04
Change at Week 16-36.8 ± 20.40-23.7 ± 21.25
SecondaryDouble-blind Induction Period: Change From Baseline in Pruritus NRS by Week up to Week 16

The Pruritus NRS is an 11-point scale used by participants to rate their worst pruritus (itch) severity over the past 24 hours, with 0 indicating "No itch," and 10 indicating "Worst itch imaginable." Higher scores indicated greater severity and negative change from baseline indicate no severity.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Pruritus NRS by Week up to Week 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-1.543 ± 1.6304-1.113 ± 1.7468
Change at Week 3-2.199 ± 2.0960-1.420 ± 2.1401
Change at Week 4-2.351 ± 2.2558-1.450 ± 2.3924
Change at Week 5-2.771 ± 2.4152-1.485 ± 2.4553
Change at Week 6-3.053 ± 2.3975-1.711 ± 2.5330
Change at Week 7-3.204 ± 2.4643-1.823 ± 2.5263
Change at Week 8-3.080 ± 2.4552-1.856 ± 2.5670
Change at Week 9-3.283 ± 2.5105-1.861 ± 2.5872
Change at Week 10-3.245 ± 2.6101-1.529 ± 2.7489
Change at Week 11-3.285 ± 2.5484-1.776 ± 2.7302
Change at Week 12-3.388 ± 2.6195-1.853 ± 2.3583
Change at Week 13-3.326 ± 2.6697-2.053 ± 2.5284
Change at Week 14-3.313 ± 2.6843-1.948 ± 2.4181
Change at Week 15-3.366 ± 2.5291-1.938 ± 2.5245
Change at Week 16-3.476 ± 2.5453-2.183 ± 2.4246
SecondaryDouble-blind Induction Period: Change From Baseline in the Sleep Loss at Week 16 Using Patient-related Outcome (PRO) by Week up to Week 16

Sleep loss was assessed by all participants using a PRO instrument. Participants (and if applicable, with help of parents/caregiver if required) rate their sleep on a 5-point Likert scale (with scores ranging from 0 \[not at all\] to 4 \[unable to sleep at all\]). Higher scores indicated a greater impact and worse outcome; therefore, negative change from baseline indicate less impact.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in the Sleep Loss at Week 16 Using Patient-related Outcome (PRO) by Week up to Week 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-0.603 ± 0.6985-0.493 ± 0.8407
Change at Week 3-0.816 ± 0.8809-0.673 ± 1.0262
Change at Week 4-0.875 ± 0.9387-0.577 ± 1.0885
Change at Week 5-0.942 ± 0.9646-0.607 ± 1.1342
Change at Week 6-0.998 ± 0.9088-0.613 ± 1.0641
Change at Week 7-1.038 ± 0.9388-0.661 ± 1.1119
Change at Week 8-0.974 ± 0.9941-0.708 ± 1.1500
Change at Week 9-1.052 ± 0.9352-0.668 ± 1.0604
Change at Week 10-1.091 ± 0.9624-0.560 ± 1.1349
Change at Week 11-1.040 ± 0.9966-0.676 ± 1.0938
Change at Week 12-1.123 ± 1.0281-0.721 ± 1.0768
Change at Week 13-1.069 ± 0.9776-0.797 ± 1.1037
Change at Week 14-1.072 ± 1.0446-0.809 ± 1.0751
Change at Week 15-1.096 ± 0.9819-0.756 ± 1.0891
Change at Week 16-1.201 ± 0.9775-0.857 ± 1.0615
SecondaryDouble-blind Induction Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Weeks 4, 8, 12 and 16

The POEM is a 7-item, validated questionnaire completed by the participant (and, if applicable, with help of parents/caregiver if required) to assess disease symptoms. Participants are asked to respond to questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping. All answers carry equal weight, with a total possible score ranging from 0 to 28 (answers scored as: No days = 0; 1 to 2 days = 1; 3 to 4 days = 2; 5 to 6 days = 3; every day = 4. Higher scores indicated more severe disease and poor quality of life (QoL); therefore, negative change from baseline indicate improvement in QoL.

Time frame:
Baseline, Weeks 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Weeks 4, 8, 12 and 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 4-8.4 ± 6.82-4.7 ± 6.42
Change at Week 8-10.9 ± 7.45-5.2 ± 6.65
Change at Week 12-11.3 ± 8.08-5.1 ± 7.25
Change at Week 16-11.9 ± 8.01-5.8 ± 7.18
SecondaryDouble-blind Induction Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 2. 4, 8, 12 and 16

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question was scored on a 4-point scale (ranged from 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, giving a total score ranging from 0 (not at all) to 30 (very much). A high score is indicative of a poor QoL and negative change from baseline indicate improvement in QoL.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 2. 4, 8, 12 and 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-4.6 ± 5.54-4.5 ± 6.00
Change at Week 4-7.1 ± 6.54-5.4 ± 6.86
Change at Week 8-8.3 ± 7.03-5.7 ± 7.89
Change at Week 12-8.7 ± 7.38-5.9 ± 7.90
Change at Week 16-9.5 ± 7.40-8.1 ± 7.62
SecondaryDouble-blind Induction Period: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2. 4, 8, 12 and 16

The CDLQI is validated from adolescents younger than age of 16 years, which is based on a set of 10 questions different from those of the DLQI to measure the impact of AD disease on QoL in children during the previous week. Each question is scored as follows: 0=not at all or unanswered, 1 = only a little, 2 = quite a lot and 3 = very much. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question, ranged from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). Higher scores indicate higher impact on QoL and negative change from baseline indicate low impact on QoL.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 2. 4, 8, 12 and 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-2.9 ± 3.41-3.6 ± 3.25
Change at Week 4-5.1 ± 4.76-4.3 ± 4.65
Change at Week 8-6.6 ± 6.69-6.9 ± 4.82
Change at Week 12-7.7 ± 7.60-7.4 ± 6.30
Change at Week 16-7.7 ± 6.91-6.8 ± 5.73
SecondaryDouble-blind Induction Period: Change From Baseline in Skin Pain NRS by Week up to Week 16

The Skin Pain NRS is an 11-point scale completed by participants to rate their worst skin pain (example, discomfort or soreness) severity over the past 24 hours, with 0 (indicating "No pain") to 10 (indicating "Worst pain imaginable). Higher scores indicated worse pain and negative change from baseline indicate no pain.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Reported as:
Mean · Score on a Scale
Double-blind Induction Period: Change From Baseline in Skin Pain NRS by Week up to Week 16
Score on a ScaleDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Change at Week 2-1.546 ± 1.7978-0.905 ± 1.9170
Change at Week 3-2.152 ± 2.1719-1.316 ± 2.2680
Change at Week 4-2.308 ± 2.2457-1.271 ± 2.4880
Change at Week 5-2.589 ± 2.3577-1.333 ± 2.4462
Change at Week 6-2.862 ± 2.4428-1.309 ± 2.5079
Change at Week 7-2.886 ± 2.4473-1.656 ± 2.4816
Change at Week 8-2.872 ± 2.4975-1.711 ± 2.7208
Change at Week 9-3.017 ± 2.4897-1.598 ± 2.5693
Change at Week 10-3.017 ± 2.6017-1.382 ± 2.7463
Change at Week 11-3.116 ± 2.6230-1.572 ± 2.6465
Change at Week 12-3.115 ± 2.6181-1.520 ± 2.5976
Change at Week 13-3.140 ± 2.5568-1.788 ± 2.4726
Change at Week 14-3.035 ± 2.6733-1.683 ± 2.4462
Change at Week 15-3.138 ± 2.6062-1.781 ± 2.6443
Change at Week 16-3.302 ± 2.5844-1.831 ± 2.5766
SecondaryDouble-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days

TCS free days proportion = Number of days participant did not take TCS medication / Number of days from Baseline to Week 16 Date or early discontinuation

Time frame:
Baseline up to Week 16
Reported as:
Mean · Proportion of Days
Double-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days
Proportion of DaysDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Proportion of Topical Corticosteroids (TCS) Medication Free Days0.224 ± 0.34910.151 ± 0.3032
SecondaryDouble-blind Induction Period: Median Time (Days) to TCS-Free Use

Days from first study drug injection to the day participant stopped using all TCS.

Time frame:
Baseline up to Week 16
Reported as:
Median · Days
Double-blind Induction Period: Median Time (Days) to TCS-Free Use
DaysDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCS
Double-blind Induction Period: Median Time (Days) to TCS-Free UseNA (NA to NA)NA (NA to NA)

Adverse events

Collected over Double-blind Induction Period: Day 1 to Week 16; Open-label Maintenance Period: Week 16 to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Induction Period: Lebrikizumab +TCS0/220 (0%)3/220 (1.4%)84/220 (38.2%)
Double-blind Induction Period: Placebo +TCS0/111 (0%)1/111 (0.9%)31/111 (27.9%)
Open-label Maintenance Period: Lebrikizumab to Lebrikizumab0/212 (0%)12/212 (5.7%)108/212 (50.9%)
Open-label Maintenance Period: Placebo to Lebrikizumab0/100 (0%)4/100 (4%)48/100 (48%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSOpen-label Maintenance Period: Lebrikizumab to LebrikizumabOpen-label Maintenance Period: Placebo to Lebrikizumab
Cutaneous T-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2200/1110/2121/100
Autoimmune thyroiditisEndocrine disorders0/2200/1110/2121/100
Abdominal painGastrointestinal disorders0/2200/1110/2121/100
Uterine polypReproductive system and breast disorders0/2200/1110/2121/100
Diabetes mellitusMetabolism and nutrition disorders0/2200/1112/2120/100
AsthmaRespiratory, thoracic and mediastinal disorders0/2200/1112/2120/100
Dermatitis atopicSkin and subcutaneous tissue disorders0/2201/1111/2120/100
BronchitisInfections and infestations0/2200/1111/2120/100
Lower respiratory tract infectionInfections and infestations0/2200/1111/2120/100
Respiratory tract infectionInfections and infestations0/2200/1111/2120/100
Most frequent other events
Most frequent other events
EventDouble-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSOpen-label Maintenance Period: Lebrikizumab to LebrikizumabOpen-label Maintenance Period: Placebo to Lebrikizumab
NasopharyngitisInfections and infestations28/22014/11152/21216/100
ConjunctivitisInfections and infestations25/2202/11125/21211/100
Conjunctivitis allergicEye disorders18/2203/11118/21211/100
Upper respiratory tract infectionInfections and infestations8/2207/11117/2126/100
COVID-19Infections and infestations8/2207/11113/2124/100
Dermatitis atopicSkin and subcutaneous tissue disorders0/2200/11112/2122/100
HeadacheNervous system disorders6/2206/1110/2120/100
Oral herpesInfections and infestations11/2203/1110/2120/100

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants and were analyzed under the treatment group as randomized.

Age, Continuous
Age, Continuous(Years)Double-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSTotal
Mean33.7 ± 14.8534.1 ± 15.2433.8 ± 14.96
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSTotal
Female10056156
Male12055175
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSTotal
Hispanic or Latino141428
Not Hispanic or Latino19793290
Unknown or Not Reported9413
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-blind Induction Period: Lebrikizumab +TCSDouble-blind Induction Period: Placebo +TCSTotal
American Indian or Alaska Native101
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American505
White206104310
More than one race022
Unknown or Not Reported729
08

Study locations

48 sites
  • Alm Site 1
    Graz, Austria
  • Alm Site 2
    Gent, Belgium
  • Alm Site 14
    Bordeaux, France
  • Alm Site 17
    Le Mans, France
  • Alm Site 19
    Lille, France
  • Alm Site 20
    Lille, France
  • Alm Site 13
    Martigues, France
  • Alm Site 16
    Nantes, France
  • Alm Site 15
    Nice, France
  • Alm Site 18
    Pierre-Bénite, France
  • Alm Site 12
    Reims, France
  • Alm Site 28
    Bad Bentheim, Germany
  • Alm Site 30
    Berlin, Germany
  • Alm Site 24
    Blankenfelde, Germany
  • Alm Site 32
    Bonn, Germany
  • Alm Site 31
    Frankfurt, Germany
  • Alm Site 27
    Göttingen, Germany
  • Alm Site 26
    Hamburg, Germany
  • Alm Site 29
    Kiel, Germany
  • Alm Site 25
    Marburg, Germany
  • Alm Site 34
    Bergen Op Zoom, Netherlands
  • Alm Site 33
    Rotterdam, Netherlands
  • Alm Site 35
    Utrecht, Netherlands
  • Alm Site 45
    Białystok, Poland
  • Alm Site 43
    Chorzów, Poland
  • Alm Site 38
    Katowice, Poland
  • Alm Site 41
    Kraków, Poland
  • Alm Site 46
    Kraków, Poland
  • Alm Site 39
    Lublin, Poland
  • Alm Site 48
    Ostrowiec Świętokrzyski, Poland
  • Alm Site 44
    Rzeszów, Poland
  • Alm Site 36
    Szczecin, Poland
  • Alm Site 42
    Warsaw, Poland
  • Alm Site 47
    Warszawa, Poland
  • Alm Site 40
    Wrocław, Poland
  • Alm Site 37
    Łódź, Poland
  • Alm Site 10
    Alicante, Spain
  • Alm Site 3
    Badalona, Spain
  • Alm Site 6
    Barcelona, Spain
  • Alm Site 8
    Barcelona, Spain
  • Alm Site 4
    Bilbao, Spain
  • Alm Site 5
    Madrid, Spain
  • Alm Site 11
    Mieres, Spain
  • Alm Site 7
    Sevilla, Spain
  • Alm Site 9
    Zaragoza, Spain
  • Alm Site 23
    Poole, United Kingdom
  • Alm Site 22
    Salford, United Kingdom
  • Alm Site 21
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 13 months.

Results were first posted in Nov 2024, 1 year 9 months after primary completion. A results delay was requested in Jan 2024.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2021
First posted
Dec 8, 2021
StartActual
Dec 23, 2021
Primary completionActual
Jan 30, 2023
CompletionActual
May 7, 2024
Results delay requested
Jan 30, 2024
Results first posted
Nov 6, 2024
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05149313
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Dec 23, 2021
Primary completion
Jan 30, 2023
Completion
May 7, 2024
Results posted
Nov 6, 2024
Last update
May 20, 2025

Study contacts

Study Director
study director · Almirall, S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion